Skip to search formSkip to main contentSkip to account menu

evolocumab

Known as: AMG 145, AMG-145 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
  • N. KandaF. Okajima
  • 2019
  • Corpus ID: 195879794
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that targets the low-density lipoprotein (LDL… 
2017
2017
Alirocumab and evolocumab are 2 human monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9… 
2017
2017
Dear Sir,Proprotein convertase subtilisin-kexin type 9 (PCSK9) is a protease that binds to the extracellular compartment of the… 
2015
2015
Rationale: Vitamin E transport and steroidogenesis are closely associated with low-density lipoproteins (LDLs) metabolism, and… 
2015
2015
Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular disease (CVD) morbidity and mortality. Statins are… 
2014
2014
1. Stein EA, Giugliano RP, Koren MJ, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to…